Arcturus Therapeutics shares slipped 55% after COVID vaccine data were considered ‘overwhelming’.
Shares of biotechnology company Arcturus Therapeutics Holdings Inc. declined 55% on Tuesday as investors reacted to the results of a Phase 1/2 trial of its COVID-19 vaccine candidate, which an anal…
